What is Shield Therapeutics?
Shield Therapeutics is a de-risked, commercial-stage pharmaceutical company focused on delivering innovative specialty pharmaceuticals to address critical unmet patient needs. The company's core mission is to improve patients' quality of life, enabling them to fully engage in their daily activities. Its flagship product, Feraccru®, is an established treatment for iron deficiency in adults, protected by exclusive intellectual property rights extending into the mid-2030s. Feraccru® is currently commercialized across the European Union through Norgine BV, with a New Drug Application (NDA) under review by the U.S. Food and Drug Administration (FDA), anticipating a decision by July 27, 2019.
How much funding has Shield Therapeutics raised?
Shield Therapeutics has raised a total of $28.2M across 3 funding rounds:
Series A
$8.2M
Debt
$10M
Share Placement
$10M
Series A (2011): $8.2M with participation from Inventages Venture Capital Investment Inc.
Debt (2022): $10M led by AOP Orphan International
Share Placement (2024): $10M, investors not publicly disclosed
Key Investors in Shield Therapeutics
Inventages Venture Capital Investment Inc.
Inventages Venture Capital Investment Inc. is a prominent venture capital fund manager with a global focus on life sciences, nutrition, and wellness. They actively support portfolio companies in strategy development, financial transactions, executive recruitment, and identifying exit opportunities, leveraging extensive ties within the pharmaceutical and private equity sectors.
What's next for Shield Therapeutics?
The recent major strategic investment in Shield Therapeutics, alongside its established enterprise-level funding, positions the company for significant growth and market penetration. This capital infusion is expected to accelerate the commercialization of Feraccru®, particularly in the crucial U.S. market pending FDA approval. Further development of its specialty pharmaceutical pipeline and strategic partnerships are likely next steps, leveraging the company's strong IP portfolio and de-risked commercial stage.
See full Shield Therapeutics company page
